SCHEMBL4033295

SCHEMBL4033295

COc1ccc(-c2n[nH]c3c(Cl)cccc23)cc1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.46
PDE4B Q07343 1/20 0.46
PDE4C Q08493 1/20 0.46
PDE4D Q08499 1/20 0.46
CHEK1 O14757 1/20 0.43
FLT3 P36888 1/20 0.43
PLK3 Q9H4B4 1/20 0.43
LCK P06239 2/20 0.43
BTK Q06187 2/20 0.43
NR3C1 P04150 1/20 0.42
PTGS2 P35354 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.39
ITK Q08881 1/20 0.39
TUBB4A P04350 2/20 0.39
TUBB P07437 2/20 0.39
TUBA3C P0DPH7 2/20 0.39
TUBA1B P68363 2/20 0.39
TUBA4A P68366 2/20 0.39
TUBB4B P68371 2/20 0.39
TUBB3 Q13509 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4028605 0.88 PDE4A (0.49) PDE4APDE4BPDE4CPDE4DCHEK1
SCHEMBL5423128 0.79 MAPK10 (0.54) PDE4APDE4BPDE4CPDE4DCHEK1
SCHEMBL1407655 0.78 CHEK1 (0.50) CHEK1FLT3PLK3MEN1KMT2A
SCHEMBL1407521 0.78 PDE4A (0.47) PDE4APDE4BPDE4CPDE4DPTGS2
SCHEMBL1407747 0.74 CYP1A2 (0.46) CHEK1FLT3PLK3ITKALDH1A1
SCHEMBL6315146 0.74 PDE4B (0.46) PDE4BPDE4DIDO1ALDH1A1MAPK1
SCHEMBL8502544 0.73 SIK2 (0.46) NR3C1PTGS2L3MBTL1CYP17A1PTGS1
SCHEMBL4034365 0.72 CHEK1 (0.50) CHEK1FLT3PLK3IDO1
SCHEMBL3949672 0.72 PDE4A (0.52) PDE4APDE4BPDE4CPDE4DPTGS2
SCHEMBL4031235 0.71 ESR1 (0.61) PDE4APDE4BPDE4CPDE4DPTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1542976-B1 SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES WYETH CORP (US) 2009-02-04 EP disclosed
US-20070225349-A1 Substituted 4-(Indazol-3-yl)phenols WYETH (US) 2007-09-27 US disclosed
US-7241791-B2 Substituted 4-(indazol-3-yl)phenols WYETH (US) 2007-07-10 US disclosed
EP-1542976-A1 SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES Wyeth (US) 2005-06-22 EP disclosed
US-20040167127-A1 Substituted 4-(indazol-3-yl)phenols WYETH (US) 2004-08-26 US disclosed
WO-2004031159-A1 SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES WYETH (US) 2004-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225349-A1 Substituted 4-(Indazol-3-yl)phenols INSR, TNNI3, INSRR PDE4A 2031/4885PDE4B 1500/4885PDE4C 1884/4885
US-20040167127-A1 Substituted 4-(indazol-3-yl)phenols INSR, MSR1, TNNI3 PDE4A 3028/4885PDE4B 2384/4885PDE4C 3003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.